FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
RegulatoryapprovedselpercatinibPositive
AI Analysis
Summary
The FDA has granted traditional approval to selpercatinib for the treatment of locally advanced or metastatic RET fusion-positive solid tumors. This regulatory milestone represents a significant achievement for the drug's development program.
Outcome Details
FDA grants traditional approval
Importance:9/10
Sentiment:
0.90
FDA approvaltraditional approvalRET fusion-positivesolid tumorsoncology
Related Companies
Read the original article
Published by FDA Drugs (New Approvals & NDA) on July 14, 2026 6:08 PM